M alignancy and ischemic stroke are both major causes of morbidity and mortality. In an autopsy study, 15% of cancer patients had cerebral infarction, and further studies have confirmed the association between stroke and cancer. [1] [2] [3] Cancer predisposes to stroke by tumor causing occlusion or emboli, malignancy-associated hypercoagulability, infection, and paraneoplastic phenomena. 1, [4] [5] [6] Regarding cancer treatment, therapeutic irradiation can cause accelerated atherosclerosis. 7 Hormonal therapy and chemotherapy have been associated with an increased risk of cerebrovascular complications. 8, 9 Cancer patients have a higher in-hospital poststroke mortality rate than those without cancer. 10 Cancer patients with cryptogenic stroke have higher D-dimer levels and more frequently infarcts located in multiple vascular territories than patients with stroke associated with other pathogenesis.
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identified from a prospective computerized hospital discharge database and entered into the Helsinki Young Stroke Registry. 17 Ischemic stroke was defined according to the World Health Organization definition as a focal neurological deficit persisting over 24 hours with correlative ischemic radiological findings or based on radiological ischemic findings with a correlative clinical picture. We excluded 4 patients who were judged to have had stroke mimics during their later follow-up and 2 patients who were lost to follow-up after having moved abroad.
Baseline Data
Baseline laboratory and other diagnostic tests are described in Methods in the online-only Data Supplement. 17 Stroke pathogenesis was assessed by the Trial of Org 10 172 in Acute Stroke Treatment (TOAST) criteria, 20 with further modifications revealing the specific underlying causes in young and middle-aged ischemic stroke patients. Cardioembolic strokes (TOAST 2) were divided into low-risk sources, which included a patent foramen ovale with or without an atrial septal aneurysm, or a sole atrial septal aneurysm, and high-risk sources consisting of all other sources. 21 Other determined pathogenesis (TOAST 4) was divided into internal carotid artery dissection, vertebral artery dissection, and rare causes other than dissection.
Follow-Up Data
We received data about all hospital admissions for all 1008 patients in primary, secondary, and tertiary inpatient units from the time period of 1969 to 1993 from the Finnish Hospital Discharge Register and from 1994 to 2011 from the Care Register for Healthcare, both of which are maintained by the National Institute for Health and Welfare, Finland. Registering of all hospital stays in the Care Register is obligatory and regulated by legislation. The discharge codes used were obtained from the International Classification of Diseases (ICD) 8th Revision (ICD-8) 1969 to 1986, a version of the 9th Revision (ICD-9) 1987 to 1995, and from the 10th Revision (ICD-10) from 1996 onwards. [22] [23] [24] The cause and the date of death were obtained from Statistics Finland.
We looked for all pre-and poststroke hospitalizations related to cancer from 1969 to 2011 with discharge diagnosis codes 140-208 according to ICD-8 and ICD-9 and C00-C97 according to ICD-10, as well as Helsinki Young Stroke Registry baseline data, and causes of death for information about cancer. 17 We considered only tumors with invasive features as cancers and excluded basal cell carcinomas and in situ lesions. The cancer diagnoses were verified and reviewed also from the patient records except for 7 patients who were treated at other institutes at the time of the diagnosis of cancer. The date of completion of the pathologist's report was considered the date of cancer diagnosis. In case the pathologist's report was not available, the arrival date of the first hospitalization for cancer was considered the date of cancer diagnosis. We recorded the number of cardiac myxomas in our patient cohort, but did not include them in the statistical analyses. Cancers diagnosed before stroke or during hospitalization for stroke were classified as prestroke cancers and those diagnosed after the hospitalization as poststroke cancers. We further divided the cancers into (1) brain and other central nervous system cancers; (2) breast cancer; (3) gastrointestinal and hepatobiliary cancers, including pancreatic cancer; (4) head and neck cancer; (5) lung and respiratory tract cancers; (6) lymphoma; (7) melanoma; (8) prostate and urinary tract cancers; and (9) other or unknown primary cancer types according to their anatomic location and histopathologic features. Data about local and systemic metastases were collected.
We classified the relation between cancer and the pathogenesis of stroke as follows: (1) cancer-related stroke, indicating active cancer without any other apparent cause for stroke; (2) cryptogenic stroke with a history of cancer, that is, cancer in history but no macroscopic cancer was detectable at the time of stroke onset; (3) cryptogenic stroke with later diagnosed cancer; (4) other etiology with a history of cancer, that is, the individual had cancer in history, but there was no detectable cancer at the time of stroke onset, and there was another apparent cause for stroke; and (5) other etiology with later diagnosed cancer. Patients with radiotherapy to head and neck cancer in history were considered to have other etiology with a history of cancer. We collected data about prestroke chemotherapy, hormonal therapy, radioiodine treatment, therapeutic irradiation, and curative or palliative surgery.
Data about all recurrent ischemic or hemorrhagic strokes and cerebral venous thrombosis were retrieved from the Care Register and from the Statistics Finland. Of the 134 recurrent strokes, 126 were verified from the patient hospital records and 6 from death records, and in 2 cases, detailed data were not available.
All data were coded anonymously in the study database. The study protocol was approved by an institutional Ethics Committee (Dnro 73/13/03/00/11; approved on April 12, 2012) and by the National Institute of Health and Welfare, Finland (Dnro THL/956/5.05.00/2012, approval date November 12, 2012).
Statistical Analysis
Statistical analyses were performed with a SPSS 21.0 computer program for Macintosh (SPSS Inc., IBM, Armonk). An interquartile range was reported for the medians. Two-sided values of P<0.05 were considered significant. Frequency tables were analyzed with either Pearson's χ 2 test or Fisher exact test. Cumulative mortality between groups was analyzed with the Kaplan-Meier life-table method using the log-rank test. Factors associated with mortality were identified with the multivariable Cox proportional hazards model. A multivariable model with backward stepwise selection was used; significant (P<0.10) variables in univariable analyses were included in the model. We constructed separate multivariable Cox proportional hazards models-adjusted for known prognostic factors for mortality in this patient population-to study the effect of following cancer-related parameters as compared with patients without cancer: (1) any cancer; (2) primary cancer location (a multiple dichotomized variable); (3) prestroke and poststroke cancer; and (4) cancer-stroke-etiology classification. Furthermore, we constructed a multivariable model to test the impact of presence of any metastases (5) among the cancer patients using cancer patients without metastases as the reference group.
Results
The characteristics of the study population are shown in Table  I in the online-only Data Supplement. Of the 1002 young and middle-aged ischemic stroke patients included in this study, 77 (7.7%) patients had cancer diagnosed at any time. Of these, 36 (3.6%) were diagnosed with cancer before stroke onset, 3 (0.3%) during hospitalization for stroke, and 38 (3.8%) after hospitalization. Three (0.3%) patients had both pre-and poststroke cancer with different histologies. Echocardiography was done for 598 (59.7%) patients, of whom 2 (0.2%) had cardiac myxoma. Thirty-two (3.2%) patients had systemic metastases and 7 (0.7%) regional metastases without systemic dissemination of cancer.
The median time from prestroke cancer to ischemic stroke was 4.9 (interquartile range 1.0-9.5) years and from ischemic stroke to poststroke cancer 6.7 (2.7-10.9) years. Lung and respiratory tract cancer was the largest single group of cancer diagnosed. No testicular cancers were detected. Twenty-five cancer patients had other pathogenesis for stroke (TOAST 4) with a history of cancer, whereas 10 patients suffered a cancer-related stroke (Table 1) . Prestroke cancer treatment characteristics are shown in Table II in the online-only Data Supplement.
No cancers emerged in the youngest age group of <30 years. Strokes caused by cardioembolism, small-vessel occlusion, vertebral artery dissection, and undetermined pathogenesis were more frequent among the patients without cancer compared with prestroke cancer patients. Poststroke cancer patients were more likely >40 years of age, heavy drinkers, and smokers compared with patients without cancer ( Figure) . The cumulative risk of stroke recurrence for all patients at 16 years follow-up was 21.0% (95% CI 16.6%-25.5%) and for cancer patients 22.6% (95% CI 7.8%-37.4%).
In a multivariable Cox regression analysis adjusted for sex, age, atrial fibrillation, cigarette smoking, congestive heart failure, coronary artery disease, diabetes mellitus type 1 and 2, heavy drinking, peripheral artery disease, admission NIHSS score, stroke in multiple territories, index stroke pathogenesis, and recurrent stroke, active cancer without any other apparent cause for stroke was statistically the strongest factor associated with the risk of death when compared with patients without cancer. When compared with patients without cancer, melanoma and lung/respiratory tract cancers were statistically most strongly associated with death of the different types of cancer examined. Both prestroke and poststroke cancers were independently associated with the risk of death (Table 3) .
Discussion
There are only few reports available about young and middleaged ischemic stroke patients diagnosed with cancer. [14] [15] [16] With this background, our study on consecutive and well-characterized patient population with first-ever ischemic stroke is unique.
We found that 3.9% of young patients with ischemic stroke had cancer diagnosed prestroke or during hospitalization for stroke and 3.8% had cancer detected after stroke. As a limitation, we did not have age-matched controls with follow-up in our study. However, only 3.0% of the Helsinki University Central Hospital district population aged 15 to 49 years had cancer diagnosed from 1969 to 2011 when analyzed from yearly figures of new cancer diagnoses equivalent to our study. 25 The prestroke cancer figure is slightly larger than that found in an older patient population with ischemic stroke. 10 Our results are also in line with a recent study that included also benign and unspecific neoplasms in their analysis. 26 The median time from cancer detection to ischemic stroke was 4.9 years, which is in the same order of magnitude as in a study from Norway, where it was 6.8 years.
14 As earlier observations, 10 the present findings also suggest that the traditional stroke risk factors may not markedly differ between patients with cancer and without cancer. Also contradictory results have been published on the distribution of traditional stroke risk factors. 13, 14 We found associations between heavy drinking, smoking, age >40 years, and poststroke cancer.
Cancer has been reported to be associated with cryptogenic stroke and stroke with multiple vascular territories affected and with stroke patients having elevated blood D-dimer levels. [11] [12] [13] We detected no statistically significant correlation between cancer and ischemic stroke affecting multiple territories or cancer and cryptogenic stroke in this young patient population. Embolism has been the major mechanism for ischemic stroke in cancer patients in some studies.
14,27 Our study could not confirm this potentially because of the younger age of our patients.
In a recent study performed on an older patient population, cancer patients with acute ischemic stroke faced a substantial short-term risk of recurrent ischemic stroke. 27 We did not find a statistically significant correlation between stroke recurrence and cancer, which is in line with prior findings. 6 Cancer patients with cryptogenic ischemic stroke had less favorable survival than those with known stroke mechanisms in another previous study. 28 In accordance with this finding, we found that patients with cancer-related stroke had the highest hazard ratio for death when compared with patients without cancer in the multivariable analysis. Prior cancer was an independent prognostic factor for death as found by others. 
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The strengths of our study include a long follow-up period, a large and well-defined population-based cohort, access to validated Finnish registry data, and availability of cancer treatment characteristics and many prognostic factors for stroke. The study has also limitations. The follow-up data were registry based, and thus some cancer cases that did not lead to hospitalization may have been missed, but the coverage for, for example, cervical cancer hospitalizations, has been shown to be 100% in this registry. 29 Second, we could not verify all cancer diagnoses because cancer was verified from patient records in 90.9% of the present cases.
In conclusion, we found that cancer is relatively common in patients who have ischemic stroke at an age <50 years, and active cancer at index stroke, melanoma, and lung/ respiratory tract cancers were independent prognostic factors for death in this patient population after adjustment for well-known prognostic factors for stroke. Currently, routine surveillance for cerebrovascular disease in young adult cancer survivors lacks evidence-based support, 30 but primary and secondary measures to reduce the risk of stroke may CI indicates confidence interval; CNS, central nervous system; CRS, cancer-related stroke; CSHC, cryptogenic stroke with history of cancer; CSLDC, cryptogenic stroke with later-diagnosed cancer; GI, gastrointestinal; HR, hazard ratio; OEHC, other etiology with history of cancer; and OELDC, other etiology with later-diagnosed cancer.
*Patients without cancer were the referent category. †Cancer patients without any metastases were the referent category, and the analysis was restricted to patients with cancer.
Stroke
June 2015 yet be of particular importance for young patients diagnosed with cancer.
